About
I am a qualified UK and European Patent Attorney with over 16 years' experience in the pharmaceutical and life sciences fields.
My main aim is to help my clients to achieve their key business goals by identifying, optimising and delivering an IP strategy that is individually tailored in each case. I also aim to provide high quality advice in a prompt and cost-effective manner.
I have particular experience and expertise in the handling of pharmaceutical-related inventions and in advising upon IP for pharmaceutical products (including patents, supplementary protection certificates (SPCs), regulatory data protection / data exclusivity and orphan marketing exclusivity).
My specialties include, in particular:
- patent drafting and prosecution;
- oppositions;
- due diligence exercises;
- validity / infringement advice;
- exemptions from patent infringement (research and "Bolar" exemptions); and
- extended protection for pharmaceutical products (SPCs).
I also have knowledge of the legislation and practice governing other forms of IP that are relevant to marketed pharmaceutical products (regulatory data protection / data exclusivity, orphan marketing exclusivity).
Publications
"Will changes to patent infringements attract drug research in the UK?", Expert Opinion on Therapeutic Patents, 26 March 2015
"When public policies collide: the battle to enforce second medical use patents for drugs in Europe", 24 March 2015
"Supplementary Protection Certificates: the Court of Justice of the EU will have its day after all", Scrip Regulatory Affairs, 22 December 2014
"Supplementary Protection Certificates: the never-ending saga of Article 3(a)", Scrip Regulatory Affairs, 1 December 2014
"The CJEU – for supplementary protection certificates, who needs it?", Scrip Regulatory Affairs, 24 October 2014
"Every cloud has a silver lining: Portugal's loss may be the UK's gain", Scrip Regulatory Affairs, 20 June 2014
"Three CJEU decision that answer some questions but pose many more", Journal of Intellectual Property Law and Practice, 22 April 2014
"You can count on us: UK IPO agrees to award longer term to some SPCs", Scrip Regulatory Affairs, December 2013
"Neurim wins the battle but not (yet) the war for innovators", Scrip Regulatory Affairs, September 2012
"A brave new world for supplementary protection certificates?", Life Sciences Intellectual Property Review, 2012
"Master the detail to get the most from SPCs", Business Development & Licensing Journal, April 2012
"Novartis decision completes a new model for SPCs in EU", Scrip Regulatory Affairs, April 2012
"Supplementary protection certificates: The CJEU issues its decision in two seminal cases", Bio-Science Law Review, January 2012
"European court ruling on SPCs brings relief to industry", Scrip Regulatory Affairs, January 2012
"Every day counts: why pharmaceutical companies in the EU need to make sure they get the right SPC term", Scrip Regulatory Affairs, October 2011
"Supplementary protection certificates: is a new era beckoning for combination drugs in the EU?", Scrip Regulatory Affairs, August 2011
"Hopes rise for a bright future for paediatric SPC extensions in the EU", Scrip Regulatory Affairs, August 2011
"Déjà vu at the ECJ?", Journal of Intellectual Property Law & Practice, August 2011
"Making the Most of Paediatric SPC Extensions", Regulatory Affairs Journal, Pharma, June 2008, 387-388
"Making the Most of Paediatric SPC Extensions", Regulatory Affairs Journal, Pharma, July 2007, 459-463
